Yhlo

Shenzhen Yahuilong Biological Technology Co., Ltd. was established in 2008 with a registered capital of 405 million yuan. The company is an innovative enterprise that integrates research, production, and sales, focusing on comprehensive clinical laboratory solutions. It is a leader in China's technology sector. Its main business involves the research, production, and sales of in vitro diagnostic instruments and reagents, primarily utilizing chemiluminescence immunoassay methods. The company has received numerous honors, including "National Intellectual Property Advantage Enterprise," "Provincial Industrial Design Center," "Guangdong Provincial Engineering Technology Research Center," "Most Investment-Worthy Brand in IVD In Vitro Diagnostics," "First Prize for Excellent Innovative Products in In Vitro Diagnostic Reagents at China’s 'Chuangzhixing' Cup," "Guangdong Medical Engineering Industry Patent Advantage Enterprise," "Guangdong Patent Award," "First Prize for Scientific and Technological Progress in Shenzhen," "Top 70 Innovative Enterprises in Shenzhen," "2018 Biomedical/Life Innovation Health Industry Innovation Achievement Award," and "Top 50 Leading Biotechnology Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area in 2019." The company's headquarters is located in BaoLong Science and Technology City, BaoLong Street, Longgang District. It is equipped with 17,000 square meters of clean production workshops and advanced international diagnostic reagent and instrument production lines. Since its establishment, the company's revenue has maintained rapid growth. While focusing on the domestic market, YHLO has actively expanded into international markets, with products exported to Europe, the Middle East, Southeast Asia, Africa, Australia, and the Americas, gaining recognition and favor from global customers. The company currently has four major in vitro diagnostic technology platforms: chemiluminescence, immunoblotting, immunofluorescence, and enzyme-linked immunosorbent assays. Its product range covers business areas such as autoimmune diseases, infectious immunity, reproductive health, diabetes, cardiovascular conditions, tumor monitoring, and endocrine metabolism. Over 300 products are widely used in hospitals, health centers, community clinics, and third-party testing centers, breaking the monopoly of international brands and replacing imported products. As of December 2019, the company has applied for more than 210 patents, of which over 70% are invention patents and more than 10% are PCT patents.